QUOTE AND NEWS
SeekingAlpha  Oct 2  Comment 
By InsiderInsights: Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights...
SeekingAlpha  Oct 2  Comment 
By Christopher F. Davis: Synta Pharmaceuticals (NASDAQ:SNTA) has just filed a form 4 with the Securities Exchange Commission. Recall that a form 4 refers to insider transactions at the company. Well, at Synta, there has been a huge wave of insider...
SeekingAlpha  Sep 22  Comment 
By Christopher F. Davis: Now is not the time for fear in Synta Pharmaceuticals (NASDAQ:SNTA). I'm writing this article in response to the flood of inquiries I have received about the stock. Let me be very, very clear about something. The stock is...
SeekingAlpha  Aug 18  Comment 
By Kanak Kanti De: Synta Pharmaceuticals Corp. (NASDAQ:SNTA) was one of those rare biotech stocks that missed out on a rally last year. Synta, which is developing the experimental cancer drug, ganetespib, struggled as investors were disappointed...
SeekingAlpha  Aug 11  Comment 
ByChristopher F. Davis: It has been some time since I have opined on Synta Pharmaceuticals (NASDAQ:SNTA). Since my last piece on Seeking Alpha covering this company, which was published on December 30, 2013, I have completed my PhD in...
FiercePharma  Aug 11  Comment 
Less than a week after mysteriously leaving a prestigious post as president of Sanofi's North American pharma unit, Anne Whitaker has tackled a rather different challenge, accepting the CEO job at Synta Pharmaceuticals, a company that has...
SeekingAlpha  Aug 6  Comment 
Synta Pharmaceuticals (NASDAQ:SNTA) Q2 2014 Earnings Call August 06, 2014 10:00 am ET Executives Daniel Cole - Keith R. Gollust - Executive Chairman of The Board, Chairman of Executive Committee, Member of Audit Committee and Member...
newratings.com  Aug 6  Comment 
WASHINGTON (dpa-AFX) - Synta Pharmaceuticals Corp. (SNTA) reported a net loss for the second quarter of $22.3 million or $0.24 per share, compared to a net loss of $22.8 million or $0.33 per share for the year-ago quarter. Analysts polled by...
StreetInsider.com  Aug 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Synta+Pharma+%28SNTA%29+Taps+Sanofi%27s+%28SNY%29+Anne+Whitaker+as+CEO/9725070.html for the full story.





You may also be interested in articles related to Synta Pharmaceuticals (SNTA):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki